Wedbush Thinks Kala Pharmaceuticals Inc’s Stock is Going to Recover


Wedbush analyst Liana Moussatos reiterated a Buy rating on Kala Pharmaceuticals Inc (NASDAQ: KALA) yesterday and set a price target of $51. The company’s shares opened today at $12.92, close to its 52-week low of $11.39.

According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 1.1% and a 42.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.

Kala Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $35.67, implying a 176.1% upside from current levels. In a report issued on August 16, H.C. Wainwright also reiterated a Buy rating on the stock with a $35 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $26.75 and a one-year low of $11.39. Currently, Kala Pharmaceuticals Inc has an average volume of 213.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company, focused on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases.

Read More on KALA:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts